Left atrial appendage closure (LAAC) is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AF).
On March 13, 2015, the U.S. Food and Drug Administration approved the WATCHMAN™ LAAC Implant, from Boston Scientific, to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular AF who are at increased risk of stroke and are recommended for blood thinning medicines, are suitable for warfarin and have an appropriate reason to seek a non-drug alternative to warfarin. The Watchman implant was studied in two randomized clinical trials and several clinical registries. The implant was approved in Europe in 2009.

Market Analysis and Insights: Global Left Atrial Appendage (LAA) Closure Market
The global Left Atrial Appendage (LAA) Closure market size is projected to reach US$ 709 million by 2027, from US$ 245.8 million in 2020, at a CAGR of 15.8% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Left Atrial Appendage (LAA) Closure market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Left Atrial Appendage (LAA) Closure market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Left Atrial Appendage (LAA) Closure market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Left Atrial Appendage (LAA) Closure market.

Global Left Atrial Appendage (LAA) Closure Scope and Market Size
Left Atrial Appendage (LAA) Closure market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Left Atrial Appendage (LAA) Closure market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Epicardial LAA Closure Device
Endocardial LAA Closure Device

Segment by Application
Hospitals
ASCs
Specialty Clinic

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AtriCure
Boston Scientific
Coherex Medical
Abbott
Occlutech
Lifetech Scientific
SentreHEART